Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cynata Therapeutics Limited ( (AU:CYP) ) just unveiled an announcement.
Cynata Therapeutics Limited announced a change in the interests of its director, Dr. Geoffrey Brooke, with the expiration of 2,000,000 unlisted options exercisable at $0.97 on November 29, 2025. This change reflects a reduction in Dr. Brooke’s holdings, which may impact the company’s stock dynamics and investor perceptions, although the overall strategic direction of the company remains unaffected.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapies using stem cell technology. The company is known for its innovative approach to regenerative medicine, targeting various medical conditions with its proprietary Cymerus™ technology.
YTD Price Performance: 18.75%
Average Trading Volume: 207,705
Technical Sentiment Signal: Buy
Current Market Cap: A$67.67M
Find detailed analytics on CYP stock on TipRanks’ Stock Analysis page.